Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Top Cited Papers
- 25 August 2015
- journal article
- guideline
- Published by Elsevier BV in Annals of Oncology
- Vol. 26 (uppl_5), v126-v132
- https://doi.org/10.1093/annonc/mdv297
Abstract
The European incidence of malignant melanoma varies from 3 to 5/100 000/year in Mediterranean countries to 12–25 (and rising) in Nordic countries. Increased ultraviolet (UV) light exposure of a genetically predisposed population seems to be, at least in part, responsible for an ongoing increase in incidence with signs of stabilisation of mortality over recent decades, except in elderly males [1]. There is a disparity in the mortality-to-incidence ratios between Western and Eastern European countries [2], implying a need to improve prevention, especially in Eastern Europe.This publication has 58 references indexed in Scilit:
- RAS Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF InhibitorsJournal of Clinical Oncology, 2012
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationThe New England Journal of Medicine, 2011
- The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of originPigment Cell & Melanoma Research, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- Final Version of 2009 AJCC Melanoma Staging and ClassificationJournal of Clinical Oncology, 2009
- Sentinel-Node Biopsy or Nodal Observation in MelanomaThe New England Journal of Medicine, 2006
- The Conundrum of Follow-Up: Should it be Abandoned?Surgical Oncology Clinics of North America, 2006
- Cutaneous melanomaThe Lancet, 2005
- Final results of the EORTC 18871/DKG 80-1 randomised phase III trial: rIFN-α2b versus rIFN-γ versus ISCADOR M® versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasisEuropean Journal of Cancer, 2004
- Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant RecipientsClinical Infectious Diseases, 2001